Expleo Solutions Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Expleo SolutionsDer Gewinn pro Aktie wird voraussichtlich um 26.8% pro Jahr wachsen.

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

26.8%

EPS-Wachstumsrate

IT Gewinnwachstum	11.1%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	17 Jul 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Expleo Solutions' (NSE:EXPLEOSOL) Conservative Accounting Might Explain Soft Earnings

Nov 22

Expleo Solutions Limited's (NSE:EXPLEOSOL) CEO Compensation Is Looking A Bit Stretched At The Moment

Aug 24

When Should You Buy Expleo Solutions Limited (NSE:EXPLEOSOL)?

Jun 21

Investors Could Be Concerned With Expleo Solutions' (NSE:EXPLEOSOL) Returns On Capital

Mar 15

The Returns On Capital At Expleo Solutions (NSE:EXPLEOSOL) Don't Inspire Confidence

Sep 15

Increases to Expleo Solutions Limited's (NSE:EXPLEOSOL) CEO Compensation Might Cool off for now

Aug 19

Calculating The Fair Value Of Expleo Solutions Limited (NSE:EXPLEOSOL)

Jul 14

Many Would Be Envious Of Expleo Solutions' (NSE:EXPLEOSOL) Excellent Returns On Capital

May 05

A Look At The Fair Value Of Expleo Solutions Limited (NSE:EXPLEOSOL)

Mar 15

Expleo Solutions Limited's (NSE:EXPLEOSOL) Stock Been Rising: Are Strong Financials Guiding The Market?

Feb 15

Expleo Solutions (NSE:EXPLEOSOL) Knows How to Allocate Capital

Jan 24

Introducing Expleo Solutions (NSE:EXPLEOSOL), A Stock That Climbed 76% In The Last Year

Jan 04

A Look At The Intrinsic Value Of Expleo Solutions Limited (NSE:EXPLEOSOL)

Dec 14

Is There More To The Story Than Expleo Solutions's (NSE:EXPLEOSOL) Earnings Growth?

Nov 26

Gewinn- und Umsatzwachstumsprognosen

NSEI:EXPLEOSOL - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (INR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2025	11,322	N/A	N/A	N/A	1
9/30/2024	10,171	1,091	1,522	1,697	N/A
6/30/2024	9,919	942	N/A	N/A	N/A
3/31/2024	9,649	904	517	692	N/A
12/31/2023	9,405	1,038	N/A	N/A	N/A
9/30/2023	9,305	1,251	130	380	N/A
6/30/2023	9,152	1,311	N/A	N/A	N/A
3/31/2023	9,033	1,339	-211	231	N/A
12/31/2022	5,072	823	N/A	N/A	N/A
9/30/2022	4,779	648	73	420	N/A
6/30/2022	4,439	583	N/A	N/A	N/A
3/31/2022	7,425	677	-12	242	N/A
12/31/2021	3,703	463	N/A	N/A	N/A
9/30/2021	3,366	475	529	588	N/A
6/30/2021	3,131	490	N/A	N/A	N/A
3/31/2021	3,009	504	620	664	N/A
12/31/2020	2,971	534	N/A	N/A	N/A
9/30/2020	2,931	512	332	373	N/A
6/30/2020	2,852	475	N/A	N/A	N/A
3/31/2020	2,702	399	144	167	N/A
12/31/2019	2,627	353	N/A	N/A	N/A
9/30/2019	2,614	298	274	295	N/A
6/30/2019	2,741	345	N/A	N/A	N/A
3/31/2019	2,865	362	382	406	N/A
12/31/2018	2,973	372	N/A	N/A	N/A
9/30/2018	2,949	377	N/A	N/A	N/A
6/30/2018	2,898	313	N/A	N/A	N/A
3/31/2018	2,764	320	N/A	250	N/A
12/31/2017	2,583	256	N/A	N/A	N/A
9/30/2017	2,488	243	N/A	N/A	N/A
6/30/2017	2,475	230	N/A	N/A	N/A
3/31/2017	2,599	238	N/A	423	N/A
12/31/2016	2,747	293	N/A	N/A	N/A
9/30/2016	2,809	329	N/A	N/A	N/A
6/30/2016	2,790	372	N/A	N/A	N/A
3/31/2016	2,642	369	N/A	577	N/A
12/31/2015	2,445	279	N/A	N/A	N/A
9/30/2015	2,312	271	N/A	N/A	N/A
6/30/2015	2,212	240	N/A	N/A	N/A
3/31/2015	2,142	216	N/A	334	N/A
12/31/2014	2,116	222	N/A	N/A	N/A
9/30/2014	2,087	226	N/A	N/A	N/A
6/30/2014	2,027	261	N/A	N/A	N/A
3/31/2014	1,944	300	N/A	237	N/A
12/31/2013	1,819	300	N/A	N/A	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Unzureichende Daten, um festzustellen, ob das prognostizierte Gewinnwachstum von EXPLEOSOL über der Sparquote liegt (6.7%).

Ertrag vs. Markt: Unzureichende Daten, um festzustellen, ob die Gewinne von EXPLEOSOL schneller wachsen werden als der Markt Indian

Hohe Wachstumserträge: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von EXPLEOSOL in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von EXPLEOSOL schneller wachsen werden als der Markt von Indian.

Hohe Wachstumseinnahmen: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Einnahmen von EXPLEOSOL schneller wachsen werden als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von EXPLEOSOL in 3 Jahren voraussichtlich hoch sein wird

Expleo Solutions Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 38% to ₹1,353

Recent updates

Expleo Solutions' (NSE:EXPLEOSOL) Conservative Accounting Might Explain Soft Earnings

Second quarter 2025 earnings released: EPS: ₹22.86 (vs ₹13.22 in 2Q 2024)

Expleo Solutions Limited Appoints Manjunathan Chinnanagounder, Director - Human Resources as Senior Management Personnel

Expleo Solutions Limited Announces Cessation of Lilian Jessie Paul as Independent Director

Expleo Solutions Limited Announces Reconstitution of Board Committees

High number of new directors

Expleo Solutions Limited Announces the Resignation of Rajesh Kumaraswamy, Senior Director - Group Services - HR, Senior Management Personnel, Last Working Day Will Be December 31, 2024

Expleo Solutions Limited Approves Appointment of Phani Tangirala as Chief Executive Officer

Expleo Solutions Limited Approves Board Appointments

Expleo Solutions Limited's (NSE:EXPLEOSOL) CEO Compensation Is Looking A Bit Stretched At The Moment

Price target increased by 38% to ₹1,353

Expleo Solutions Limited Not Recommends Any Dividend for the Financial Year 2023 - 2024

Expleo Solutions Limited, Annual General Meeting, Aug 29, 2024

Expleo Solutions Limited to Report Q1, 2025 Results on Aug 01, 2024

Expleo Solutions Limited Announces Closing of Expleo Solutions FZE, UAE, Wholly Owned Subsidiary

Expleo Solutions Limited to Report Fiscal Year 2024 Results on May 23, 2024

Expleo Solutions Limited Announces Directorate Changes

New minor risk - Profit margin trend

Third quarter 2024 earnings released: EPS: ₹21.93 (vs ₹28.22 in 3Q 2023)

Expleo Solutions Limited to Report Q3, 2024 Results on Feb 07, 2024

Expleo Solutions Limited Announces Chief Financial Officer Changes

Expleo Solutions Limited Announces the Resignation of Prashant Eknath Bramhankar as Whole-Time Director & COO

Second quarter 2024 earnings released: EPS: ₹13.22 (vs ₹17.17 in 2Q 2023)

Expleo Solutions Limited to Report Q2, 2024 Results on Nov 09, 2023

Insufficient new directors

Investor sentiment deteriorates as stock falls 20%

Expleo Solutions Limited Declare Final Dividend for the Financial Year 2022-23

Expleo Solutions Limited to Report Q1, 2024 Results on Aug 10, 2023

Full year 2023 earnings released: EPS: ₹86.27 (vs ₹43.61 in FY 2022)

Expleo Solutions Limited Proposes to Declare Final Dividend for Financial Year 2022-23

Upcoming dividend of ₹5.00 per share at 0.3% yield

Full year 2023 earnings released: EPS: ₹86.27 (vs ₹52.58 in FY 2022)

Expleo Solutions Limited Recommends Dividend for the Financial Year Ended March 31, 2023, Payable on or Before September 09, 2023

Expleo Solutions Limited, Annual General Meeting, Aug 10, 2023

Third quarter 2023 earnings released: EPS: ₹28.22 (vs ₹11.10 in 3Q 2022)

Second quarter 2023 earnings released: EPS: ₹17.17 (vs ₹10.80 in 2Q 2022)

Second quarter 2023 earnings released: EPS: ₹17.17 (vs ₹10.80 in 2Q 2022)

Senior Director of BFSI recently sold ₹1.3m worth of stock

Full year 2022 earnings released

Investor sentiment improved over the past week

Expleo Solutions Limited to Report Q4, 2023 Results on May 29, 2023

When Should You Buy Expleo Solutions Limited (NSE:EXPLEOSOL)?

Senior Director of BFSI recently sold ₹5.7m worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Expleo Solutions Limited, Annual General Meeting, Aug 11, 2022

Expleo Solutions Limited (NSEI:EXPLEOSOL) acquired Lucid Technologies & Solutions.

Investors Could Be Concerned With Expleo Solutions' (NSE:EXPLEOSOL) Returns On Capital

Senior Director of BFSI recently sold ₹1.4m worth of stock

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

Insider recently sold ₹1.4m worth of stock

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS ₹10.80 (vs ₹12.27 in 2Q 2021)

The Returns On Capital At Expleo Solutions (NSE:EXPLEOSOL) Don't Inspire Confidence

Increases to Expleo Solutions Limited's (NSE:EXPLEOSOL) CEO Compensation Might Cool off for now

Full year 2021 earnings released: EPS ₹49.20 (vs ₹38.51 in FY 2020)

Calculating The Fair Value Of Expleo Solutions Limited (NSE:EXPLEOSOL)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹49.20 (vs ₹38.51 in FY 2020)

Investor sentiment improved over the past week

Many Would Be Envious Of Expleo Solutions' (NSE:EXPLEOSOL) Excellent Returns On Capital

Investor sentiment improved over the past week

Additional Non-Executive Director has left the company

A Look At The Fair Value Of Expleo Solutions Limited (NSE:EXPLEOSOL)

Expleo Solutions Limited's (NSE:EXPLEOSOL) Stock Been Rising: Are Strong Financials Guiding The Market?

Third quarter 2021 earnings released: EPS ₹12.30 (vs ₹9.96 in 3Q 2020)

Expleo Solutions Limited to Report Q3, 2021 Results on Feb 04, 2021

Expleo Solutions (NSE:EXPLEOSOL) Knows How to Allocate Capital

Introducing Expleo Solutions (NSE:EXPLEOSOL), A Stock That Climbed 76% In The Last Year

New 90-day low: ₹458

A Look At The Intrinsic Value Of Expleo Solutions Limited (NSE:EXPLEOSOL)

Is There More To The Story Than Expleo Solutions's (NSE:EXPLEOSOL) Earnings Growth?

Market pulls back on stock over the past week